Candidiasis: vulvovaginal, balanitis and complete clinical management
On this page
01
Overview
Candidiasis is caused by overgrowth of Candida yeasts, most often C. albicans. Vulvovaginal candidiasis (VVC) is usually endogenous rather than a classic sexually transmitted infection, but sexual activity can contribute to irritation and occasional transmission. Recurrent or complicated disease requires confirmation because bacterial vaginosis, trichomoniasis, dermatitis, herpes and diabetes can look similar. Invasive candidiasis is a separate, life-threatening illness seen mainly in hospitalised or immunocompromised patients.
Do not diagnose VVC from itch alone: examine, test the discharge when possible, identify non-albicans species and look for diabetes, antibiotics, pregnancy or immunosuppression.
02
Learning objectives
- Distinguish uncomplicated, severe, recurrent, complicated and non-albicans VVC.
- Recognise male balanitis, oral disease and invasive candidiasis.
- Use pH, microscopy, culture/NAAT and clinical findings to establish diagnosis.
- Select safe treatment in pregnancy, diabetes, HIV and recurrent disease, with correct doses.
- Counsel patients about partner care, hygiene, recurrence prevention and when to refer.
03
Organism and predisposition
Candida is part of normal mucosal flora in many people. Disease follows altered vaginal ecology, increased oestrogen, antibiotic exposure, diabetes, pregnancy, HIV or immunosuppression. Most VVC is C. albicans; C. glabrata and other non-albicans species are less susceptible to standard azoles and are common in recurrent disease. VVC is not proof of partner infidelity or poor hygiene.
Scroll the table sideways on a smaller screen.
| Pattern | Definition/setting | Clinical implication |
|---|---|---|
| Uncomplicated VVC | Infrequent, mild–moderate, likely C. albicans, immunocompetent | Short topical or single-dose oral azole regimen |
| Severe VVC | Marked erythema, oedema, fissures or excoriations | Longer topical course or repeat oral dosing |
| Recurrent VVC | At least three symptomatic episodes in a year | Culture/speciation and induction plus maintenance plan |
| Complicated/non-albicans | Pregnancy, diabetes, HIV, immunosuppression or resistant species | Confirm diagnosis and specialist-directed treatment |
04
Clinical features
Vulvovaginal candidiasis
Intense vulval itch, soreness, burning, dyspareunia, dysuria from external inflammation and thick white, usually non-offensive discharge are typical. Examination may show erythema, oedema, excoriations and fissures. The discharge is not always clumpy, and absence of odour does not prove candidiasis.
Male candidal balanitis
Itching, burning, erythematous glans, small papules, moist patches and fissuring may occur, particularly with diabetes, antibiotics or a symptomatic partner. Recurrent balanitis warrants diabetes testing and assessment for phimosis or dermatoses.
Oral and oesophageal disease
Creamy plaques that scrape away leaving an erythematous base, angular cheilitis, sore mouth or odynophagia suggest mucosal candidiasis. Oesophageal symptoms require systemic therapy and assessment for HIV or other immunosuppression.
Invasive candidiasis
Persistent fever or sepsis, central-line exposure, abdominal surgery, neutropenia or prolonged antibiotics raise concern for candidaemia. This is not managed with topical vaginal medication.
05
History and examination
- Ask about onset, recurrence count, pregnancy, menstrual relation, antibiotics, diabetes, HIV, steroids, contraception and prior treatments.
- Clarify odour, colour, pelvic pain, fever, bleeding, urinary symptoms, dyspareunia and STI exposure.
- Inspect vulva, vagina, cervix, penis and oral mucosa; assess for ulcers, vesicles, cervical motion tenderness or dermatoses.
- Check glucose/HbA1c, HIV status and medication interactions when disease is recurrent or complicated.
06
Diagnosis
- Vaginal pH is usually normal (<4.5) in VVC; a higher pH suggests bacterial vaginosis or trichomoniasis, though mixed infection can occur.
- Wet mount with saline and KOH may show budding yeast or pseudohyphae; a negative microscopy does not exclude disease.
- Culture or validated NAAT is recommended for recurrent, severe, persistent or non-albicans disease and before prolonged suppression.
- Do not treat asymptomatic colonisation except in specific specialist situations; a positive culture must match symptoms and examination.
- Consider gonorrhoea, chlamydia, trichomoniasis, bacterial vaginosis, genital herpes, contact dermatitis, lichen sclerosus and desquamative inflammatory vaginitis.
07
Management
Uncomplicated VVC
A recommended topical azole course (see the drug table below) or a single dose of oral fluconazole where appropriate and not contraindicated. Explain correct intravaginal application and that azole creams may weaken latex condoms and diaphragms temporarily.
Pregnancy
Use only topical azoles for the recommended longer course. Avoid oral fluconazole in pregnancy unless a specialist specifically directs otherwise. Examine persistent symptoms rather than repeatedly treating empirically.
Severe VVC
A longer topical azole regimen or repeat oral dosing under current guidelines. Assess for fissures, oedema, diabetes and mixed infection; review if symptoms do not improve.
Recurrent VVC
Obtain culture/speciation, address diabetes or antibiotic exposure, then use guideline-based induction followed by suppressive therapy for the recommended duration (e.g., fluconazole 150 mg weekly for 6 months after an induction course). Recurrence after stopping suppression is common and requires reassessment.
Non-albicans Candida
Exclude other causes and use a longer non-fluconazole azole regimen or specialist-directed alternative. Avoid repeated fluconazole when susceptibility is unlikely; refractory disease merits specialist input.
08
Drug summary table
Scroll the table sideways on a smaller screen.
| Drug | Dose | Indication | Adverse effects / cautions |
|---|---|---|---|
| Clotrimazole (topical/pessary) | VVC: 500 mg pessary as a single dose at night, or 200 mg pessary nightly for 3 nights, or 100 mg nightly for 6 nights; add 1–2% cream to the vulva BD for 1–2 weeks. Balanitis: 1–2% cream BD for 1–2 weeks | First-line uncomplicated VVC; balanitis; preferred in pregnancy (use the 7-day course) | Local burning or irritation; creams damage latex condoms/diaphragms while in use; complete the full course even when itch settles early |
| Miconazole (topical; oral gel) | 2% cream BD 1–2 weeks for skin/balanitis/intertrigo; oral gel 10–20 mL QDS (swallowed slowly after food) for oral thrush | Candidal intertrigo, balanitis, oral thrush | Same latex caution as other azole creams; oral gel: nausea, taste disturbance |
| Fluconazole (oral) | Uncomplicated VVC: 150 mg as a single oral dose. Severe VVC: repeat 150 mg after 72 hours. Recurrent VVC: 150 mg every 72 h for 3 doses, then 150 mg weekly for 6 months. Oral thrush: 100–200 mg daily for 7–14 days. Oesophageal candidiasis: 200–400 mg daily for 14–21 days | Oral or single-dose therapy for VVC, thrush and oesophageal disease when systemic treatment is needed | Avoid in pregnancy (teratogenic risk, especially first trimester) and with QT-prolonging drugs; interactions — raises levels of warfarin, phenytoin, some statins and sulfonylureas; nausea, headache, hepatic reactions uncommonly |
| Nystatin (oral suspension) | Oral thrush: 100,000 units/mL — 4–6 mL QDS, swish and swallow; continue 48 h after clinical cure; infants 1–2 mL QDS | Oral thrush, especially in infants, pregnancy and where systemic azoles are unsuitable | Essentially non-absorbed, so very safe; poor palatability; not effective for vaginal or systemic disease |
| Ketoconazole 2% shampoo / cream | Shampoo as a short-contact wash for extensive intertrigo or pityriasis versicolor adjuncts; cream BD for 2 weeks for skin candidiasis | Skin and fold candidiasis; seborrhoeic dermatitis overlap | Limit topical use to skin; oral ketoconazole is avoided for routine candidiasis because of hepatotoxicity |
| Amphotericin B / echinocandin (e.g., caspofungin) | Hospital protocol — e.g., amphotericin B 0.5–1 mg/kg/day IV or caspofungin 70 mg loading then 50 mg daily IV; fluconazole 800 mg loading then 400 mg daily is an alternative for stable, fluconazole-susceptible candidaemia | Invasive candidiasis/candidaemia only — never topical treatment | Renal toxicity (amphotericin), infusion reactions; monitor electrolytes, renal and hepatic function; specialist-directed |
09
Partner care and sexual health
Routine treatment of an asymptomatic male partner is not recommended for uncomplicated VVC. Symptomatic balanitis should be examined and treated with appropriate topical therapy (clotrimazole cream), while recurrent couple-associated symptoms may justify assessment of both partners. Advise abstinence or condoms until pain and inflammation settle. Screen for other STIs when history or examination indicates risk; candidiasis alone does not establish an STI.
10
Prevention and self-care
- Avoid unnecessary antibiotics and scented vaginal products, douching and harsh soaps.
- Keep the area dry, use breathable underwear and change out of wet clothing.
- Optimise glycaemic control and HIV treatment; do not rely on probiotics as a substitute for therapy.
- Explain medication adherence and avoid stopping treatment as soon as itch improves in recurrent disease.
- Seek review for fever, pelvic pain, ulcers, pregnancy, recurrent episodes or failure after treatment.
11
When candidiasis is not the answer
Fishy odour, thin grey discharge and clue cells suggest bacterial vaginosis. Frothy yellow-green discharge and strawberry cervix suggest trichomoniasis. Vesicles or painful ulcers suggest herpes. Cervical motion tenderness, fever or lower abdominal pain raises PID. Vulval fissures, white plaques or architectural change may indicate dermatosis and require specialist assessment.
12
Invasive candidiasis red flags
Hospitalised patients with fever or shock, central venous catheters, recent abdominal surgery, neutropenia, renal replacement therapy or persistent candidaemia require blood cultures, source control (remove infected lines), systemic antifungal treatment and evaluation for metastatic infection including retinal and cardiac (endophthalmitis, endocarditis) involvement. Vaginal treatment is never adequate for candidaemia.
13
Clinical scenario
Scenario 1 — The pregnant woman with itch
A 26-year-old woman at 24 weeks of pregnancy has intense vulval itch, thick white discharge and no odour. pH is 4.2 and microscopy shows budding yeast and pseudohyphae — vulvovaginal candidiasis in pregnancy. Treat with topical clotrimazole 100 mg pessary nightly for 7 nights (or the 200 mg nightly for 3 nights course) plus 1–2% cream to the vulva; do not give oral fluconazole. Explain that pregnancy hormones predispose to recurrence, that creams weaken condoms during treatment, and that persistent symptoms warrant review rather than repeated over-the-counter courses. Reassure her that VVC in pregnancy is common, not a sign of infidelity, and is not known to harm the baby.
Scenario 2 — Four episodes this year
A 38-year-old woman with HIV on antiretroviral therapy presents with her fourth episode of VVC this year. She has been treating each episode with single-dose fluconazole from a pharmacy, with only partial relief. Recurrent VVC is a clue, not a nuisance: check HbA1c/fasting glucose, review HIV viral load and CD4, and send a culture with speciation. If C. albicans is confirmed, use an induction course (fluconazole 150 mg every 72 h for 3 doses) followed by suppressive fluconazole 150 mg weekly for 6 months. If a non-albicans species such as C. glabrata is found, fluconazole is often ineffective — use a longer topical regimen or specialist-directed alternatives. Counsel her not to self-treat future episodes without review, and check for drug interactions (her fluconazole may raise levels of any sulfonylurea or warfarin she takes).
14
Exam pearls
- VVC usually has normal vaginal pH; BV and trichomoniasis usually raise it.
- Recurrent VVC requires culture/speciation and evaluation for diabetes or immunosuppression.
- Topical azoles are preferred in pregnancy; avoid routine oral fluconazole.
- Asymptomatic Candida colonisation does not automatically require treatment.
- Persistent symptoms after treatment demand a new diagnosis, not automatic retreatment.
15
Key points
16
References
- SlideShare: Candidiasis (Library reference.)
- Uganda Clinical Guidelines: Candidiasis (Library reference.)
- WHO/CDC guidance for vulvovaginal and invasive candidiasis (Library reference.)
- British National Formulary (BNF) — antifungal doses (Library reference.)
17
Further reading
For deeper study, compare this lesson with current guidance and standard references from recognised medical and public-health organisations.
For education only. Apply current Uganda Clinical Guidelines, local protocols and specialist advice in clinical practice.